Riley Jennifer 4
4 · Avalo Therapeutics, Inc. · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Avalo (AVTX) CSO Jennifer Riley Receives 95,000-Share Option Grant
What Happened
Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics (AVTX), received a derivative award on February 26, 2026: 95,000 shares reported as acquired at $0.00. This was an award/option grant (not an open-market purchase or sale) and carries a multi-year vesting schedule rather than immediate ownership or a cash transaction.
Key Details
- Transaction date: 2026-02-26; Instrument: derivative award (stock option/award) — 95,000 units at $0.00.
- Vesting: 25% vests on February 26, 2027; the remainder vests in equal monthly installments over the following three years, subject to continued service (footnote).
- Shares owned after transaction: not specified in the provided filing.
- Filing: Form 4 filed 2026-03-02 (appears timely based on the Feb 26 transaction date).
- No 10b5-1 plan, tax-withholding sale, or cashless exercise noted in the provided details.
Context
This was a compensation-related derivative grant (stock option/award) that vests over time. It is not an immediate purchase or sale and therefore does not directly signal a near-term buy or sell of Avalo stock; such grants are common executive compensation.
Insider Transaction Report
Form 4
Riley Jennifer
Chief Strategy Officer
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-02-26+95,000→ 95,000 totalExercise: $17.64Exp: 2036-02-26→ Common Stock (95,000 underlying)
Footnotes (1)
- [F1]The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.
Signature
/s/ Christopher Sullivan, Attorney-in-Fact|2026-03-02